IRIS
RIZZI, Rita
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.217
AS - Asia 5.996
EU - Europa 5.710
SA - Sud America 1.759
Continente sconosciuto - Info sul continente non disponibili 405
AF - Africa 303
OC - Oceania 16
Totale 29.406
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.803
SG - Singapore 2.536
IT - Italia 2.201
CN - Cina 1.400
BR - Brasile 1.380
HK - Hong Kong 757
SE - Svezia 669
RU - Federazione Russa 565
DE - Germania 468
UA - Ucraina 451
FR - Francia 386
FI - Finlandia 383
VN - Vietnam 370
GB - Regno Unito 272
IN - India 194
CA - Canada 188
BD - Bangladesh 158
AR - Argentina 131
CI - Costa d'Avorio 97
ID - Indonesia 81
TR - Turchia 70
IQ - Iraq 65
CO - Colombia 60
MX - Messico 60
NL - Olanda 58
ZA - Sudafrica 53
EC - Ecuador 52
IE - Irlanda 48
PL - Polonia 45
VE - Venezuela 44
JP - Giappone 43
SA - Arabia Saudita 43
PK - Pakistan 42
ES - Italia 35
MA - Marocco 33
CL - Cile 28
IL - Israele 28
UZ - Uzbekistan 28
JM - Giamaica 27
BE - Belgio 25
PY - Paraguay 25
TN - Tunisia 24
CR - Costa Rica 22
CZ - Repubblica Ceca 22
JO - Giordania 22
PE - Perù 21
EG - Egitto 19
GT - Guatemala 18
PH - Filippine 18
PR - Porto Rico 18
CW - ???statistics.table.value.countryCode.CW??? 17
TT - Trinidad e Tobago 17
AU - Australia 15
HN - Honduras 15
MY - Malesia 15
LT - Lituania 14
AE - Emirati Arabi Uniti 13
AT - Austria 13
ET - Etiopia 13
KE - Kenya 12
NI - Nicaragua 12
SC - Seychelles 12
SV - El Salvador 12
AZ - Azerbaigian 11
IR - Iran 10
TH - Thailandia 10
UY - Uruguay 10
KR - Corea 9
KZ - Kazakistan 9
NP - Nepal 9
GP - Guadalupe 8
BO - Bolivia 7
OM - Oman 7
PS - Palestinian Territory 7
HR - Croazia 6
SN - Senegal 6
TW - Taiwan 6
BY - Bielorussia 5
EU - Europa 5
LY - Libia 5
XK - ???statistics.table.value.countryCode.XK??? 5
AL - Albania 4
AO - Angola 4
CH - Svizzera 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
LB - Libano 4
MD - Moldavia 4
MN - Mongolia 4
MU - Mauritius 4
RO - Romania 4
AM - Armenia 3
BG - Bulgaria 3
BN - Brunei Darussalam 3
BS - Bahamas 3
DK - Danimarca 3
EE - Estonia 3
GE - Georgia 3
HU - Ungheria 3
LC - Santa Lucia 3
Totale 28.968
Salva come PNG Salva come JPEG
Città #
Ashburn 2.106
Singapore 1.326
San Jose 1.188
Jacksonville 1.022
Chandler 1.013
Woodbridge 894
Fairfield 825
Hong Kong 735
Milan 710
Houston 544
Nyköping 470
Ann Arbor 455
Cambridge 431
Council Bluffs 370
Seattle 335
Beijing 329
Wilmington 299
Roxbury 256
New York 252
Rome 252
Lawrence 242
Nanjing 239
Lauterbourg 238
Los Angeles 193
Dallas 189
Boardman 188
São Paulo 171
Des Moines 162
Bari 156
Helsinki 128
Ho Chi Minh City 126
Santa Clara 121
Inglewood 107
Abidjan 96
Columbus 95
Princeton 89
Brooklyn 86
Buffalo 79
Hanoi 75
Shenyang 72
Hebei 66
Florence 63
Toronto 63
London 61
San Diego 57
Jiaxing 52
Dearborn 51
Turin 51
Chicago 49
Phoenix 47
Dublin 46
Nanchang 46
Figino 44
Munich 44
Montreal 43
Changsha 41
Moscow 39
Rio de Janeiro 39
Falkenstein 37
Jakarta 37
Nuremberg 37
Tianjin 37
Paris 36
Tokyo 35
Frankfurt am Main 33
Guangzhou 33
San Francisco 33
Atlanta 32
Baghdad 32
Chennai 32
Naples 32
Orem 32
The Dalles 32
Johannesburg 31
Warsaw 30
Pune 28
Belo Horizonte 26
Tashkent 26
Turku 26
Brasília 25
Curitiba 25
Brussels 24
Dhaka 22
Medellín 22
Redwood City 22
Washington 22
North Bergen 21
Denver 20
Charlotte 18
Istanbul 18
Jinan 18
San José 18
Amsterdam 17
Bologna 17
Manchester 17
Quito 17
Willemstad 17
Campinas 16
Guatemala City 16
Noicattaro 16
Totale 18.651
Salva come PNG Salva come JPEG
Nome #
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese" 224
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 222
Leucemia linfatica cronica in trasformazione prolinfocitoide: descrizione di un caso 219
LIGHT/TNFSF14 as a new biomarker of bone disease in multiple myeloma patients experiencing therapeutic regimens 207
Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM) 205
A role of light as potential biomarker for progression of smoldering to symptomatic multiple myeloma 199
Ibridizzazione in situ non isotopica. Attualità e prospettive 184
Non-treatment-related chronic myeloid leukemia as a second malignancy 182
CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP) 181
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 180
A case of AL amyloidosis associated with IgD multiple myeloma (MM): clinical and laboratory findings, and outcome 177
Vascular Endothelial Growth Factor Serum Levels Are Elevated in Patients with Hereditary Hemorrhagic Telangiectasia 177
Amyloid in bone marrow smears of patients affected by multiple myeloma 175
ANALYSIS OF PROGNOSTIC FACTORS AND TIME TO FIRST TREATMENT IN YOUNG PATIENTS (<55 YEARS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A SINGLE CENTER EXPERIENCE 174
TRAIL effect on osteoclast formation in physiological and pathological conditions 174
Alteration of the osteogenic properties of bone marrow stromal cells from multiple myeloma bone disease patients 171
Acute tubular necrosis in the hemlock poisoning 167
Alteration of bone remodeling in multiple myeloma bone disease: role of sclerostin 165
Light/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. 164
Concomitant primary polycythemia vera and follicle center cell non-Hodgkin lymphoma: a case report and review of the literature 163
CD34CD2 Acute promyelocytic leukemia (APL): is this a distinct subset? 162
LIGHT/TNFSF14 Promotes Osteolytic Bone Metastases in Non-small Cell Lung Cancer Patients 161
Behçet's disease: an immune-mediated vasculitis involving vessels of all sizes 160
How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia 158
A rare case of IgM-Multiple Myeloma 155
Alterazione delle capacità osteogeniche in cellule stromali ottenute da midollo osseo di pazienti affetti da mieloma multiplo 154
DARA-VD VERSUS DARA-RD AS SALVAGE THERAPY FOR PATIENTS WITH MYELOMA. INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY RETE EMATOLOGICA PUGLIESE 154
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients 152
Analysis of percent identity of IGHV mutation as prognostic factor in CLL patients treated with fludarabine, cyclofosfamide and rituximab: a single centre experience 152
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials 152
The role of multiparameter flow cytometry in the work-up of IGM-monoclonal gammopathies 151
A Phase III study of enoxaparin versus aspirin versus low-dose warfarin as thrombophylaxis for patients with newly diagnosed multiple myeloma treated up-front with thalidomide based-regimens 151
A case of light chain (AL) amyloidosis associated with IgD Multiple Myeloma (MM): clinical features, laboratory findings and outcome 148
T cells support osteoclastogenesis in an in vitro model derived from psoritic arthritis 147
Autoimmune Myelofibrosis: report of three cases and review of the literature 146
A weekly infusion of bortezomib reduces peripheral neuropathy 146
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 146
Kidney damage by ingestion of ethylene glicol 144
Anti-endothelial cell antibodies (AECA) in a patient wiyh Takayasu’s arteritis. In: Pathogenesis and immunotherapy of autoimmune diseases. Final program and abstract book 144
Sclerostin is overexpressed by plasma cells from multiple myeloma patients 144
Immunogenicity of two idiotypes with a different immunoglobulin-chain distribution expressed on the same anti-CD4 Mab 144
Soluble Decoy Receptor 3 (DcR3) modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients 143
Hepatitis C virus infection and mixed cryoglobulinemia: a striking association 142
Amyloidosis: clinical picture, immunological and biomolecular features, treatment prospects 140
Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion 139
T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction 139
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts 138
Altered osteogenic properties of bone marrow stromal cells from multiple myeloma patients 138
Another link between bone and immune system: LIGHT 137
Rhabdomyolysis and acute tubular necrosis in coniine (hemlock)poisoning 136
A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase 136
Livelli sierici di VEGF in pazienti affetti da Sindrome di Rendu-Osler-Weber 134
REAL-WORLD ITALIAN EXPERIENCE OF POMALIDOMIDE IN RELAPSED-REFRACTORY MYELOMA: RETROSPECTIVE MULTICENTER STUDY BY THE RETE EMATOLOGICA PUGLIESE AND BASILICATA 134
A prospective randomized study comparing rituximab and dexamethasone vs dexamethasone alone in ITP: results of final analysis and long term follow up 133
Autoimmune hemolytic anemia during interferon-alfa therapy for chronic hepatitis C 133
Takayasu’s arteritis: a cell mediated large vessel vasculitis 133
DEDALO: PHASE II STUDY OF DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION 132
The OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease 132
A phase II study of chlorambucil + rituximab (CLB-R) followed by R maintenance vs observation in elderly patients with previously untreated chronic lymphocytic leukemia (CLL): induction phase results 132
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance 131
A phase II Study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: results of the first interim analysis 130
Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients 129
T cells support the in vitro formation of osteoclasts in multiple myeloma-bone disease: the role of OPG/TRAIL interaction 128
Infection complications in patients with multiple myeloma treated with new drug combinations including thalidomide 128
Myeloma cells suppress osteoblasts through sclerostin secretion 128
L'AMILOIDOSI: QUADRI CLINICI, CARATTERISTICHE IMMUNOLOGICHE E BIOMOLECOLARI, PROSPETTIVE TERAPEUTICHE 127
The Role of LIGHT in Multiple Myeloma-Bone Disease 127
In vitro osteoclastogenesis and T-cell RANKL expression in multiple myeloma-bone disease at diagnosis and in the setting of frontline treatment 126
LIGHT INVOLVEMENT IN MULTIPLE MYELOMA-OSTEOLYTIC BONE DISEASE 126
FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience 124
Anti-endothelial cell autoantibodies in patients with Behcet’s disease 124
Irisin prevents trabecular bone damage and tumor invasion in a mouse model of multiple myeloma 123
T cells support the osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease 122
The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease 122
Analysis of the prognostic value of CD20 antigen expression in chronic lymphocytic leukaemia 122
Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function 121
Malignant lymphoma involving a Warthin’s tumor: a case with immunophenotypic and gene rearrangement analysis 119
P-ANCA atipici nelle malattie infiammatorie croniche intestinali 119
What Is New in the Treatment of Smoldering Multiple Myeloma? 119
Upfront Single Versus Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial) 118
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 117
Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience 117
Clinical spectrum of accidental hemlock poisoning: neurotoxic manifestations, rhabdomyolysis and acute tubular necrosis 117
Three or Four drugs for treatment of relapsed/refractory multiple myeloma (MM): comparison between THADD and THADD-V 117
Angiogenesis and hereditary hemorrhagic telangiectasia. Rendu-Osler-Weber disease 117
DCR3 involvement in multiple myeloma bone disease 116
Bone marrow angiogenesis in autoimmune myelofibrosis 116
LIGHT: another link between bone and immune system 116
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial 116
Failure of an in vitro model of osteoclastogenesis in human plasma cell leukaemia (PCL) 116
Humoral Immune Response after anti-SARS-CoV-2 Vaccine "Booster" Dose in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) 115
Human anti-mouse antibodies interfere in the determination of sCD4 in intravenous immunoglobulin preparations 115
Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third line treatment in a poor prognosis group of adult acute myeloid leukemia patients: A single center experience 115
Anti-endothelial cell autoantibodies in Takayasu’s arteritis 112
[Treatment of supra-aortic trunk aneurysms: report on 16 cases]. FT Il trattamento degli aneurismi dei tronchi sovraaortici: esperienza su 16 casi. 112
Chirurgia degli aneurismi dei tronchi sovraaortici 112
Aneurysms of the supra-aortic trunks in Takayasu's disease - Report of two cases 112
Circulating levels of cathepsin-k in multiple myeloma patients 112
Thalidomide, dexamethasone, doxil and velcade (ThaDD-V) induction therapy followed by consolidation-maintenance is very effective in early relapsed/refractory MM 111
X-ANCA in pazienti con malattia infiammatoria cronica dell’intestino 110
Totale 14.236
Salva come PNG Salva come JPEG
Categoria #
all - tutte 120.019
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 120.019
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.324 0 0 0 0 56 77 73 96 126 79 314 503
2022/20232.648 380 231 111 271 344 375 41 300 495 16 45 39
2023/20241.332 200 212 73 66 97 238 65 69 8 55 101 148
2024/20254.078 114 55 403 140 110 366 310 344 182 187 622 1.245
2025/20268.944 1.181 365 575 970 859 524 1.094 258 873 837 261 1.147
2026/20273.629 334 533 951 1.711 100 0 0 0 0 0 0 0
Totale 29.406